Breakpoints for carbapenemase-producing Enterobacteriaceae: Is the problem solved?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 32, Issue S4, 2014, Pages 33-40

  Cantón, Rafael ^a,b   Canut, Andrés ^c   Morosini, María Isabel ^a,b   Oliver, Antonio ^b,d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Red Espanola de Investigacion en Patologia Infecciosa REIPI   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Carbapenemases; Clinical breakpoints; Enterobacteriaceae; Pharmacokinetic pharmacodynamics; PK PD breakpoints

Indexed keywords

CARBAPENEM; CARBAPENEMASE; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CLINICAL STUDY; CRITICALLY ILL PATIENT; HUMAN; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; REVIEW; ANTIBIOTIC RESISTANCE; DOSE RESPONSE; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; HEALTH SURVEY; INTERNATIONAL COOPERATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PROCEDURES; RESEARCH; STANDARDS; TIME FACTOR;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INTERNATIONAL AGENCIES; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; RESEARCH REPORT; TIME FACTORS;

EID: 84920720254     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(14)70172-7     Document Type: Article

References (52)

1. Lynch TJ. Choosing optimal antimicrobial therapies. Med Clin North Am. 2012; 96:1079-94.
2. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943-50.
3. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682-707.
4. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322-8.
5. Van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75:115-20.
6. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther. 2012;10:1393-404.
7. International Organization for Standardization (ISO). Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. International Standard 20776-1, ISO. Geneva. 2006.
8. Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother. 2012;67:1569-77.
9. Nordmann P, Poirel L. Strategies for identification of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2013;68:487-9.
10. Mouton JW, Brown DF, Apfalter P, Cantón R, Giske CG, Ivanova M, et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect. 2012;18:E37-45.
11. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN; Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin Infect Dis. 2013;56:1301-9.
12. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. Available at: http://www.eucast.org
13. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement. CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
14. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement (June 2010 update). CLSI document M100-S20-U. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
15. Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2012;18:432-8.
16. Bhavnani SM, Dudley MN, Landersdorfer L, Drusano GL, Craig WA, Jones RN, et al. Pharmacokinetic-pharmacodynamic basis for CLSI carbapenem susceptibility breakpoint changes. 50th Intersci. Conf. Antimicrob. Boston, MA; Agents Chemother; 2010. Abstract A-1382.
17. European Committee on Antimicrobial Susceptibility Testing. Imipenem: Rationale for the clinical breakpoints, version 1.3, 2009. Available at: http://www.eucast.org
18. European Committee on Antimicrobial Susceptibility Testing. Meropenem: Rationale for the clinical breakpoints, version 1.5, 2009. Available at: http://www.eucast.org
19. Giske C, Martínez-Martínez L, Cantón R, Stefani S, Skov R, Glupczynski Y, et al. EUCAST subcommittee for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 1.0. November 2013. Available at: http://www.eucast.org
20. Endimiani A, Pérez F, Bajaksouzian S, Windau AR, Good CE, Choudhary Y, et al. Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol. 2010;48:4417-25.
21. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012;16:R218.
22. Tato M, Morosini M, García L, Albertí S, Coque MT, Cantón R. Carbapenem heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J Clin Microbiol. 2010;48:4089-93.
23. Kitchel B, Rasheed JK, Endimiani A, Hujer AM, Anderson KF, Bonomo RA, et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010;54:4201-7.
24. Oteo J, Sáez D, Bautista V, Fernández-Romero S, Hernández-Molina JM, Pérez-Vázquez M, et al; Spanish Collaborating Group for the Antibiotic Resistance Surveillance Program. Carbapenemase-producing Enterobacteriaceae in Spain in 2012. Antimicrob Agents Chemother. 2013;57:6344-7.
25. Tsai YK, Liou CH, Fung CP, Lin JC, Siu LK. Single or in combination antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to varied susceptibility to different carbapenems. Plos One. 2013;8:e79640.
26. Antunes NT, Lamoureaux TL, Toth M, Stewart NK, Frase H, Vakulenko SB. Class D β-lactamases: are they all carbapenemases? Antimicrob Agents Chemother. 2014;58:2119-25.
27. Vading M, Samuelsen Ø, Haldorsen B, Sundsfjord AS, Giske CG. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Clin Microbiol Infect. 2011;17:668-74.
28. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008;47 Suppl 1:S32-40.
29. Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection. 2009;37:296-305.
30. Jenkins SG, Jerris RC. Critical assessment of issues applicable to development of antimicrobial susceptibility testing breakpoints. J Clin Microbiol. 2011;49 Suppl:S5-10.
31. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother. 2008;61:621-8.
32. Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Osterlund A, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother. 2003;52:145-8.
33. Marchese A, Esposito S, Barbieri R, Bassetti M, Debbia E. Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections? BMC Infect Dis. 2012;12: 181.
34. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nat Rev Microbiol. 2004;2:289-300.
35. Maglio D, Kuti JL, Nicolau DP. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. Clin Ther. 2005;27:1032-42.
36. Mouton JW. Setting clinical MIC breakpoints from a PK/PD point of view: it is the dose that matters. In: Vinks AA, Derendorf H, Mouton JW, editors. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. New York: Springer; 2014. p. 45-61.
37. European Committee on Antimicrobial Susceptibility Testing. Doripenem: Rationale for the clinical breakpoints, version 1.0, 2009. Available at: http://www.eucast.org
38. European Committee on Antimicrobial Susceptibility Testing. Ertapenem: Rationale for the clinical breakpoints, version 1.3, 2009. Available at: http://www.eucast.org
39. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142-50.
40. Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy. 2013;33:266-74.
41. Burkhardt O, Kumar V, Kielstein JT, Welte T, Derendorf H. Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents. 2010;35:93-9.
42. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, et al. Population pharmacokinetics and pharmacodynamics of continous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized controlled trial. Antimicrob Agents Chemother. 2007;51:3304-10.
43. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med. 2013;41:489-95.
44. Hombach M, Bloemberg GV, Böttger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother. 2012;67:622-32.
45. Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother. 2013;68:2092-8.
46. Hombach M, Wolfensberger A, Kuster SP, Böttger EC. Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods. J Clin Microbiol. 2013;51:2385-7.
47. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis. 2009;64:233-5.
48. Wolfensberger A, Sax H, Weber R, Zbinden R, Kuster SP, Hombach M. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms. PLoS One. 2013;8:e79130.
49. Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol. 2007;45:2723-5.
50. Esterly JS, Wagner J, McLaughlin MM, Postelnick MJ, Qi C, Scheetz MH. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother. 2012;56:4885-90.
51. Jean SS, Hsueh PR, Lee WS, Yu KW, Liao CH, Chang FY, et al. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009. Int J Antimicrob Agents. 2013;41:457-62.
52. Cantón R. Lectura interpretada del antibiograma: una necesidad clínica. Enferm Infecc Microbiol Clin. 2010;28:375-85.